This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Kos Biotechnology Partners Closes Fund
Business fund closing

Kos Biotechnology Partners Closes Fund

Analysis based on 8 articles · First reported Jun 13, 2026 · Last updated Jun 13, 2026

Sentiment
70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The successful third closing of Kos Biotechnology Partners' fund, raising $123 million, signals increased investment and growth potential in the global life sciences sector, particularly in Greece and Europe. This could lead to new drug discoveries and advancements in pharma services, positively impacting the biotechnology and pharmaceutical industries. The involvement of Greece — Hellenic Development Bank of Investments also highlights a supportive environment for venture capital in Greece.

Biotechnology Venture capital Pharmaceuticals
Event Summary

Kos Biotechnology Partners, a global life sciences investment firm, announced the third closing of its inaugural global life sciences fund, securing $123 million (€106 million) in total capital commitments. This fund, launched in December 2025, has attracted backing from institutional investors, including lead investor Greece — Hellenic Development Bank of Investments, and global family offices. Kos Biotechnology Partners is noted as the first life sciences-dedicated investment fund in Greece and the largest venture capital fund launch in the country's history. The firm, founded by Dr. Simos Simeonidis and Alex Tzoukas, aims to deploy strategic capital across various development stages in biotech/novel therapeutics, pharma services, and tech-enabled technologies. Nikos Kostaras has also joined as a partner. The fund has already made two investments, including leading a financing round for Epikast.

Entities Involved
priv
Kos Biotechnology Partners
Kos Biotechnology Partners announced the third closing of its inaugural global life sciences fund, raising $123 million in total capital commitments. This event solidifies its position as a significant player in the life sciences investment sector, particularly in Greece and Europe.
Importance 100.0 Sentiment 70.0
per
Simos Simeonidis
Dr. Simos Simeonidis is a Co-Founder and Managing Partner of Kos Biotechnology Partners, instrumental in securing the fund's capital commitments and driving its investment strategy. His expertise is key to the firm's mission.
Importance 80.0 Sentiment 60.0
per
Alex Tzoukas
Alex Tzoukas is a Co-Founder and Managing Partner of Kos Biotechnology Partners, playing a crucial role in the fund's successful closing and its cross-border investment thesis. His experience contributes to the firm's operational momentum.
Importance 80.0 Sentiment 60.0
govactor
Greece — Hellenic Development Bank of Investments
Greece — Hellenic Development Bank of Investments is a lead investor in the Kos Biotechnology Partners fund, contributing to its successful third closing and supporting the growth of the life sciences ecosystem in Greece.
Importance 70.0 Sentiment 50.0
per
Nikos Kostaras
Nikos Kostaras joins Kos Biotechnology Partners as the third partner, bringing operational and strategic expertise that will help implement and accelerate the fund's global strategy.
Importance 60.0 Sentiment 50.0
oth
Epikast
Epikast is a tech-enabled pharma services provider that received a lead financing round from Kos Biotechnology Partners, demonstrating the fund's initial investment activity.
Importance 40.0 Sentiment 50.0
cnt
Greece
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.